|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
GENOME TRI-CONFERENCE | ||||||||||||||||
December 06, 2000 | ||||||||||||||||
Cambridge Healthtech Institute, San Francisco, California March 3-9, 2001 This year's Genome Tri-Conference will be aimed at exploring new trends and ideas in genomic medicine. As gene databases are mined, numerous targets for diagnostic and therapeutic exploration have amassed. To take advantage of these discoveries and provide answers in the quest for new products, the deployment of sophisticated technologies is required. Learn about these emerging genomic technologies as early stage companies make presentations at the opening meeting, Genomic Partnering. Next, discover the commercial implications of new and established techniques at our core conference, Human Genome Discovery. Finally, learn about recent developments in the field of Gene Functional Analysis during the closing portion of the event. Featured topics at the tri-conference include high throughput methods, chemical genomics, microarray applications, genotyping, and proteomics. Also, using information derived from genomics to design better drugs will be covered. Researchers and executives interested in learning how to implement these strategies in their own organizations should not miss this group of conferences. Find out why CHI's Genome Tri-conference is the must attend event of the year. |
||||||||||||||||
Organized by: | Cambridge Healthtech Institute | |||||||||||||||
Invited Speakers: | Dr. Mark D. Adams, Celera Genomics Dr. Noubar B. Afeyan, NewcoGen Group and AGTC Funds Dr. Ashok Amin, New York University School of Medicine Dr. Paul R. Billings, GeneSage, Inc. Dr. Michael Boyce-Jacino, Orchid BioSciences, Inc. Dr. Andreas Braun, Sequenom, Inc. Dr. Mark Chee, Illumina, Inc. Mr. Scott Clarke, BioSpace.com Dr. Mark I. Cockett, Bristol-Myers Squibb Pharmaceutical Research Institute Dr. Robert Cook-Deegan, Georgetown University and Stanford-in-Washington Program Dr. Kenneth W. Culver, Novartis Pharmaceuticals Corporation Dr. Vishva M. Dixit, Genentech, Inc. Dr. Björn Ekström, Pyrosequencing AB Dr. Stephen P.A. Fodor, Affymetrix, Inc. Dr. Lance Fors, Third Wave Technologies, Inc. Dr. Stephen H. Friend, Rosetta Inpharmatics, Inc. Dr. David Galas, Keck Graduate Institute of Applied Life Sciences Dr. Tim Harris, Structural GenomiX, Inc. Dr. Elaine Heron, PE Applied Biosystems Dr. Arthur L. Holden, The SNP Consortium Mr. Steven H. Holtzman, Millennium Pharmaceuticals, Inc. Dr. Jon Faiz Kayyem, Clinical Micro Sensors/Motorola Dr. Klaus Lindpaintner, F. Hoffmann-La Roche AG Dr. Rich B. Meyer, Protogene Laboratories, Inc. Prof. Robert P. Merges, University of California, Berkeley School of Law Dr. Michio Oishi, Kazusa DNA Research Institute Dr. David J. O'Reilly, Iconix Pharmaceuticals, Inc. Dr. Ari Patrinos, U.S. Department of Energy Dr. Patrick Plewman, diaDexus Dr. Allen D. Roses, GlaxoWellcome Research and Development Dr. Jonathan M. Rothberg, CuraGen Corporation Dr. Steve Ruben, Human Genome Sciences Dr. Brent A. Rupnow, Hoffmann-La Roche Inc. Dr. Randy Scott, Incyte Genomics Inc. and Genomic Health, Inc. Prof. John Todd, University of Cambridge Dr. Jackson Wan, R. W. Johnson Pharmaceutical Research Institute Dr. Gregory Went, DNA Sciences Dr. David G. Wang, First Genetic Trust |
|||||||||||||||
Deadline for Abstracts: | February 2, 2001 | |||||||||||||||
Registration: | Available on-line | |||||||||||||||
E-mail: | jlaakso@healthtech.com | |||||||||||||||
Posted by: | Jennifer Laakso | |||||||||||||||
Host: | wks217.healthtech.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |